Your browser doesn't support javascript.
loading
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers.
Boruah, Nabamita; Hoyos, David; Moses, Renyta; Hausler, Ryan; Desai, Heena; Le, Anh N; Good, Madeline; Kelly, Gregory; Raghavakaimal, Ashvathi; Tayeb, Maliha; Narasimhamurthy, Mohana; Doucette, Abigail; Gabriel, Peter; Feldman, Michael J; Park, Jinae; de Rodas, Miguel Lopez; Schalper, Kurt A; Goldfarb, Shari B; Nayak, Anupma; Levine, Arnold J; Greenbaum, Benjamin D; Maxwell, Kara N.
Afiliação
  • Boruah N; Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Hoyos D; Computational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Moses R; Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Hausler R; Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Desai H; Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Le AN; Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Good M; Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Kelly G; Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Raghavakaimal A; Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Tayeb M; Department of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Narasimhamurthy M; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA.
  • Doucette A; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Gabriel P; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Feldman MJ; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Park J; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA.
  • de Rodas ML; Departments of Medicine and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Schalper KA; Department of Pathology, Yale School of Medicine, New Haven, CT.
  • Goldfarb SB; Department of Pathology, Yale School of Medicine, New Haven, CT.
  • Nayak A; Departments of Medicine and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Levine AJ; Department of Medicine, Weill Cornell Medical Center, New York, NY.
  • Greenbaum BD; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia PA.
  • Maxwell KN; Institute for Advanced Study, Princeton, NJ.
bioRxiv ; 2024 Apr 05.
Article em En | MEDLINE | ID: mdl-38617260
ABSTRACT
Pathogenic germline TP53 alterations cause Li-Fraumeni Syndrome (LFS), and breast cancer is the most common cancer in LFS females. We performed first of its kind multimodal analysis of LFS breast cancer (LFS-BC) compared to sporadic premenopausal BC. Nearly all LFS-BC underwent biallelic loss of TP53 with no recurrent oncogenic variants except ERBB2 (HER2) amplification. Compared to sporadic BC, in situ and invasive LFS-BC exhibited a high burden of short amplified aneuploid segments (SAAS). Pro-apoptotic p53 target genes BAX and TP53I3 failed to be up-regulated in LFS-BC as was seen in sporadic BC compared to normal breast tissue. LFS-BC had lower CD8+ T-cell infiltration compared to sporadic BC yet higher levels of proliferating cytotoxic T-cells. Within LFS-BC, progression from in situ to invasive BC was marked by an increase in chromosomal instability with a decrease in proliferating cytotoxic T-cells. Our study uncovers critical events in mutant p53-driven tumorigenesis in breast tissue.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article